Gisadenafil besylate

Modify Date: 2024-04-02 18:00:49

Gisadenafil besylate Structure
Gisadenafil besylate structure
Common Name Gisadenafil besylate
CAS Number 334827-98-4 Molecular Weight 677.79200
Density N/A Boiling Point N/A
Molecular Formula C29H38N7O8S2- Melting Point N/A
MSDS Chinese USA Flash Point N/A

 Use of Gisadenafil besylate


Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)[1].

 Names

Name benzenesulfonic acid,5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4H-pyrazolo[4,3-d]pyrimidin-7-one
Synonym More Synonyms

 Gisadenafil besylate Biological Activity

Description Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)[1].
Target

PDE5A:3.6 nM (IC50)

PDE1A:9.1 μM (IC50)

In Vitro Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity[1].
In Vivo Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels[1]. Animal Model: Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia[1] Dosage: 2 mg/kg Administration: Intraperitoneal injection; for 2 hours Result: Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia.
References

[1]. Silva J, et al. Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflammation. 2012 Nov 20;9:253.

[2]. Rawson DJ, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012 Jan 1;20(1):498-509.

 Chemical & Physical Properties

Molecular Formula C29H38N7O8S2-
Molecular Weight 677.79200
Exact Mass 677.23000
PSA 206.67000
LogP 4.08600

 Safety Information

RIDADR NONH for all modes of transport

 Precursor & DownStream

Precursor  2

DownStream  0

 Synonyms

GISADENAFIL BESYLATE
Gisadenafil besylate (USAN)
Gisadenafil besylate salt